CyFlow™ CD69 Purified
| Alternative Name: | AIM , VEA |
| Antibody: | Yes |
| Antigen: | CD69 |
| Application: | Flow cytometry, Functional assays, Immunohistochemistry (frozen sections) |
| Clonality: | monoclonal |
| Clone: | FN50 |
| Field of Interest: | Immunophenotyping |
| Format/Fluorochrome: | Purified |
| Isotype: | IgG1 |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | BQ969908 |
For Research Use Only
| Concentration Unit | mg/mL |
| Concentration | 1 |
| Quantity | 0.1 mg |
| Volume | 0.1 mL |
| Immunogen | Anti-μ-stimulated human B lymphocytes |
| Background Information | CD69 (CLEC2C; C-type lectin domain family 2 C or AIM) is one of the earliest inducible cell surface molecules acquired during leukocyte activation. This glycoprotein serves as a lectin-type receptor in lymphocytes, NK cells and platelets; it is involved in lymphocyte proliferation. CD69 expression is counteracted on T cells in the AIDS stage of HIV infection, and may be also predictive for clinical response to chemoimmunotherapy. |
| Storage Buffer | The reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford University Press, Oxford. 1989; 1‑1820. < NLM ID: 8914679 > | López-Cabrera M, Santis AG, Fernández-Ruiz E, Blacher R, Esch F, Sánchez-Mateos P, Sánchez-Madrid F: Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C‑type animal lectin superfamily of signal‑transmitting receptors. J Exp Med. 1993 Aug 1; 178(2):537‑47. < PMID: 8340758 > | Nielsen SD, Afzelius P, Ersbøll AK, Nielsen JO, Hansen JE: Expression of the activation antigen CD69 predicts functionality of in vitro expanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV‑infected patients. Clin Exp Immunol. 1998 Oct; 114(1):66‑72. < PMID: 9764605 > | Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single‑molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int Immunol. 2007 May; 19(5):675‑84. < PMID: 17446208 > | Tomescu C, Chehimi J, Maino VC, Montaner LJ: NK cell lysis of HIV‑1‑infected autologous CD4 primary T cells: requirement for IFN‑mediated NK activation by plasmacytoid dendritic cells. J Immunol. 2007 Aug 15; 179(4):2097‑104. < PMID: 17675468 > | Konjević G, Jović V, Vuletić A, Radulović S, Jelić S, Spuzić I: CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma. Eur J Clin Invest. 2007 Nov; 37(11):887‑96. < PMID: 17973783 > | Pitsios C, Dimitrakopoulou A, Tsalimalma K, Kordossis T, Choremi-Papadopoulou H: Expression of CD69 on T‑cell subsets in HIV‑1 disease. Scand J Clin Lab Invest. 2008; 68(3):233‑41. < PMID: 17917998 > | Hrdinka M, Dráber P, Stepánek O, Ormsby T, Otáhal P, Angelisová P, Brdicka T, Paces J, Horejsí V, Drbal K: PRR7 is a transmembrane adaptor protein expressed in activated T cells involved in regulation of T cell receptor signaling and apoptosis. J Biol Chem. 2011 Jun 3; 286(22):19617‑29. < PMID: 21460222 > | Ohradanova‐Repic A, Machacek C, Charvet C, Lager F, Le Roux D, Platzer R, Leksa V, Mitulovic G, Burkard TR, Zlabinger GJ, Fischer MB, Feuillet V, Renault G, Blüml S, Benko M, Suchanek M, Huppa JB, Matsuyama T, Cavaco‐Paulo A, Bismuth G, Stockinger H: Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances. FrontImmunol. 2018 Apr 27; 9:852. < PMID: 29780382 >